Michael Anglesio
Assistant Professor
Research Classification
Cancer of the Reproductive System
Host-Tumour Interaction
Endometriosis
Cancer Diagnosis and Detection
Research Interests
microenvironment
endometriosis associated cancers
Immunology
genomics
gene-expression and transcriptomics
Cancer prevention
ovarian cancer etiology
early detection biomarkers
animal models of endometriosis and cancer
Relevant Degree Programs
Research Methodology
molecular biology
Animal models
Next generation sequencing
transcriptomics
immunohistochemistry
laser capture microdissection
in vitro models of cancer
Recruitment
Master's students
Doctoral students
Postdoctoral Fellows
Applicants need to be self-funded
Any time / year round
1. Clinical and Genomic Determinants of Early Metastasis in Synchronous Endometrial and Ovarian Cancers (MSc or PhD)
2. Development of Pre-Cancerous Mouse Models of Endometriosis (Post doc or PhD candidate with prior MSc/model experience)
Publications
- Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging (2017)
Modern Pathology - Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes (2017)
Yi Kan Wang and Ali Bashashati and Michael S Anglesio and Dawn R Cochrane and Diljot S Grewal and Gavin Ha and Andrew McPherson and Hugo M Horlings and Janine Senz and Leah M Prentice and Anthony N Karnezis and Daniel Lai and Mohamed R Aniba and Allen W Zhang and Karey Shumansky and Celia Siu and Adrian Wan and Melissa K McConechy and Hector Li-Chang and Alicia Tone and Diane Provencher and Manon de Ladurantaye and Hubert Fleury and Aikou Okamoto and Satoshi Yanagida and Nozomu Yanaihara and Mis
Nature Genetics 49 (6) 856--865 - Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. (2015)
- Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. (2015)
- Recurrent DICER1 Hotspot Mutations in Endometrial Tumours And Their Impact on MicroRNA Biogenesis. (2015)
- Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. (2015)
- A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. (2014)
- A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. (2014)
- Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. (2014)
- Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. (2014)
- Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. (2014)
- Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. (2013)
- Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. (2013)
- Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. (2013)
- Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. (2013)
- FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. (2013)
- Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. (2013)
- Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. (2013)
- Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. (2013)
- Type-specific cell line models for type-specific ovarian cancer research. (2013)
- Benign serous ovarian tumour: a redefining moment? (2012)
- Cytokine gene expression signature in ovarian clear cell carcinoma. (2012)
- LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. (2012)
- Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. (2012)
- The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. (2012)
- Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. (2011)
- Copy number aberrations in benign serous ovarian tumors: a case for reclassification? (2011)
- Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. (2011)
- IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. (2011)
- Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. (2011)
- ARID1A mutations in endometriosis-associated ovarian carcinomas. (2010)
- Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. (2010)
- Profiling the cancer genome. (2010)
- Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. (2009)
- Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. (2008)
- The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. (2007)
- Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. (2006)
- Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. (2004)
Program Affiliations
Department(s)
If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.